Blair William & Co. IL Reduces Position in Amgen Inc. $AMGN

Blair William & Co. IL trimmed its position in Amgen Inc. (NASDAQ:AMGN) by 2.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 162,239 shares of the medical research company’s stock after selling 4,654 shares during the quarter. Blair William & Co. IL’s holdings in Amgen were worth $45,784,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Legacy Investment Solutions LLC acquired a new stake in Amgen in the second quarter valued at $27,000. Evelyn Partners Investment Management LLP acquired a new position in shares of Amgen during the 2nd quarter worth about $32,000. Howard Hughes Medical Institute acquired a new position in shares of Amgen during the 2nd quarter worth about $32,000. Cloud Capital Management LLC purchased a new position in shares of Amgen in the 3rd quarter valued at about $34,000. Finally, Nvwm LLC increased its holdings in shares of Amgen by 893.3% in the 2nd quarter. Nvwm LLC now owns 149 shares of the medical research company’s stock valued at $42,000 after acquiring an additional 134 shares during the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.

Amgen Trading Up 0.5%

NASDAQ:AMGN opened at $369.53 on Friday. The stock’s 50 day moving average price is $353.26 and its 200 day moving average price is $322.62. The company has a market capitalization of $199.20 billion, a PE ratio of 25.97, a P/E/G ratio of 3.67 and a beta of 0.45. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78. Amgen Inc. has a 52-week low of $261.43 and a 52-week high of $391.29.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, beating analysts’ consensus estimates of $4.76 by $0.53. The company had revenue of $9.87 billion during the quarter, compared to analysts’ expectations of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The firm’s revenue for the quarter was up 8.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, research analysts anticipate that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be given a $2.52 dividend. The ex-dividend date is Friday, May 15th. This represents a $10.08 annualized dividend and a yield of 2.7%. Amgen’s dividend payout ratio is 70.84%.

Analyst Ratings Changes

Several equities research analysts recently weighed in on AMGN shares. HSBC restated a “buy” rating and set a $425.00 target price on shares of Amgen in a research note on Wednesday, December 10th. Wells Fargo & Company increased their price target on shares of Amgen from $325.00 to $375.00 and gave the company an “equal weight” rating in a research note on Thursday, February 19th. Wall Street Zen downgraded shares of Amgen from a “buy” rating to a “hold” rating in a research report on Saturday, February 21st. Argus upped their target price on shares of Amgen from $360.00 to $400.00 and gave the company a “buy” rating in a report on Friday, February 6th. Finally, Scotiabank started coverage on shares of Amgen in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $385.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, twelve have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, Amgen presently has a consensus rating of “Hold” and an average target price of $354.17.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen’s recent quarter beat revenue and EPS estimates and management issued FY‑2026 EPS guidance, which supports the buy thesis and helped lift sentiment. Why Is Amgen (AMGN) Up 3.6% Since Last Earnings Report?
• Positive Sentiment: The board declared a $2.52 quarterly dividend (ex‑dividend May 15), reinforcing shareholder returns and supporting income‑oriented demand for the stock. AMGEN ANNOUNCES 2026 SECOND QUARTER DIVIDEND
• Neutral Sentiment: Amgen will present at the Leerink Partners 2026 Global Healthcare Conference (Mar 11). The fireside chat with the CFO and rare‑disease head could provide more detail on pipeline priorities and capital allocation — a potential catalyst depending on the tone. AMGEN TO PRESENT AT THE LEERINK PARTNERS 2026 GLOBAL HEALTHCARE CONFERENCE
• Neutral Sentiment: Short‑interest data reported for early March appears to show no meaningful short position (entries list zeros/NaN), which suggests short sellers are not a large immediate pressure point — note the data may reflect reporting quirks.
• Negative Sentiment: Amgen and partner Kyowa Kirin halted all rocatinlimab trials after safety signals linking OX40 pathway modulation to malignancies. Losing a late‑stage immunology asset is a clear pipeline setback and could reduce upside from future launches. Amgen Faces Rocatinlimab Halt And Rethinks Pipeline And Capital Priorities
• Negative Sentiment: Senate Democrats are pressing pharma companies over pricing deals tied to the prior administration, raising the risk of increased political and regulatory scrutiny that could pressure margins or pricing for large biopharma firms including Amgen. Pharma giants pressed by Senate Democrats over Trump pricing deals
• Negative Sentiment: At least one analyst piece has downgraded the stock to a “hold” / advised waiting for a better entry point, signaling some caution on valuation after the recent run. Amgen: Wait For A Better Entry Point (Rating Downgrade)

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.